CRO Solutions, a US-based company that provides business-development solutions to small to medium-sized contract research organisations, has launched a wholly owned subsidiary as a ‘one-stop’ platform for these niche CROs’ early-phase services.
VxP Pharma will offer pharmaceutical-development services, as well as technical support, for the development and production of medicines, diagnostics, and drug/device combinations from discovery through to Phase IIb clinical trials.
It will do so by drawing on a network of independently owned and operated ‘niche’ CROs, the majority of them located in the US (although VxP Pharma will also offer access to facilities in Europe and Asia).
All of the VxP sites have been fully audited by CRO Solutions/VxP Pharma, as well as by global pharmaceutical and biotechnology clients, the parent company noted.
Most of the sites have also been audited by the US Food and Drug Administration and by other international regulatory agencies.
Each of the partnered CROs that make up VxP Pharma specialises in just one area of drug development.
“The solid state chemistry lab only performs solid state chemistry, and the preclinical facility performs only services needed during preclinical development,” CRO Solutions explained.
“Because they focus on their core competencies, the subject matter experts at each of the locations are among the world’s best.”
Pharmaceutical and biotechnology research scientists throughout the industry “tell us that they prefer to work with smaller, focused contract research organisations, rather than with the huge multinational ‘one-size-fits-all’ CROs”, commented Raymond Peck, chief executive officer of the Indianapolis-based subsidiary.
“For these people, VxP Pharma is a perfect fit because we offer a single point of contact, as well as the confidence that, if you work with VxP, you are working with a state-of-the-art lab that has been subject to a complete audit, including, in most cases, an audit by the US FDA,” Peck added.